IL‐6R is a therapeutic target in rheumatoid arthritis (RA); a neutralizing antibody targeting the IL‐6R, tocilizumab (trade name: Actemra), is approved for the treatment of RA in adult patients (Ogata et al, 2012, 2018) and has also recently received FDA approval for the treatment of cytokine release syndrome related to CAR T‐cell therapy (Le et al, 2018). Here, IL6R is linked to rheumatoid arthritis.